Fidelity International
ALXN

Fidelity International’s Alexion Pharmaceuticals ALXN Stock Holding History

Fidelity International’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,791
Closed -$696K – 926
2021
Q2 		$696K Sell
3,791
-17,884
-83% -$3.07M ﹤0.01% 767
2021
Q1 		$3.31M Sell
21,675
-52,433
-71% -$8.11M ﹤0.01% 640
2020
Q4 		$11.6M Sell
74,108
-371,195
-83% -$47.7M 0.01% 465
2020
Q3 		$51M Sell
445,303
-78,410
-15% -$8.46M 0.06% 278
2020
Q2 		$58.8M Sell
523,713
-449,465
-46% -$47.7M 0.08% 239
2020
Q1 		$87.4M Buy
973,178
+88,728
+10% +$8.71M 0.14% 161
2019
Q4 		$95.7M Sell
884,450
-319,455
-27% -$34.2M 0.13% 186
2019
Q3 		$118M Buy
1,203,905
+134,277
+13% +$15.1M 0.18% 148
2019
Q2 		$140M Sell
1,069,628
-138,939
-11% -$17.9M 0.21% 128
2019
Q1 		$163M Buy
1,208,567
+1,042,846
+629% +$130M 0.26% 114
2018
Q4 		$16.1M Buy
165,721
+13,458
+9% +$1.59M 0.03% 377
2018
Q3 		$21.2M Buy
152,263
+1,681
+1% +$211K 0.03% 384
2018
Q2 		$18.7M Buy
150,582
+19,618
+15% +$2.29M 0.03% 406
2018
Q1 		$14.6M Buy
+130,964
New +$15.7M 0.04% 310
2017
Q3 		– Sell
-71,693
Closed -$8.72M – 531
2017
Q2 		$8.72M Hold
71,693
– – 0.03% 345
2017
Q1 		$8.69M Hold
71,693
– – 0.02% 359
2016
Q4 		$8.77M Sell
71,693
-3,706
-5% -$453K 0.03% 346
2016
Q3 		$9.24M Sell
75,399
-29,072
-28% -$3.74M 0.03% 338
2016
Q2 		$12.2M Sell
104,471
-278,292
-73% -$39.5M 0.04% 314
2016
Q1 		$53.3M Sell
382,763
-270,782
-41% -$39.8M 0.17% 132
2015
Q4 		$125M Buy
653,545
+44,434
+7% +$7.76M 0.38% 72
2015
Q3 		$95.3M Buy
609,111
+88,734
+17% +$16.2M 0.33% 83
2015
Q2 		$94.1M Buy
520,377
+452,717
+669% +$78.1M 0.3% 91
2015
Q1 		$11.7M Sell
67,660
-35,180
-34% -$6.37M 0.04% 345
2014
Q4 		$19M Buy
102,840
+3,551
+4% +$658K 0.07% 273
2014
Q3 		$16.5M Sell
99,289
-7,374
-7% -$1.21M 0.06% 271
2014
Q2 		$16.7M Buy
106,663
+2,666
+3% +$421K 0.06% 288
2014
Q1 		$15.8M Sell
103,997
-20,676
-17% -$3.29M 0.06% 296
2013
Q4 		$16.6M Buy
+124,673
New +$15M 0.07% 256

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Fidelity International's ALXN Position: Q3 2021 in Review

Fidelity International sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,791 shares — an estimated $696K sold.

Fidelity International first reported a position in ALXN in Q4 2013 and held it in 29 quarters. The position peaked at $163M in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Fidelity International reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Fidelity International sold 3,791 Alexion Pharmaceuticals shares in Q3 2021, an estimated $696K.
  • Fidelity International first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 29 quarters.
  • Fidelity International's Alexion Pharmaceuticals position peaked at $163M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Fidelity International's 13F filing for Q3 2021, filed 15 Nov 2021.